ANA Screen, IFA, Reflex Titer/Pattern
Information provided by Quest Diagnostics
Autoimmune rheumatic diseases are conditions in which the immune system attacks the joints and certain systems. They are often difficult to diagnose, as their symptoms can be vague, vary from patient to patient, and often overlap. Laboratory testing can provide useful information, but no single test provides a definitive diagnosis for any one rheumatic disease.
Diagnosis is most often based on a compilation of symptoms and signs, including clinical information and laboratory test results. Testing for antinuclear antibodies (ANAs) using an immunofluorescence assay (IFA) is a good first approach for laboratory evaluation of patients suspected of having certain autoimmune rheumatic diseases.
ANAs, a group of autoantibodies directed against diverse nuclear and cytoplasmic antigens, are associated with several autoimmune rheumatic diseases. These include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and mixed connective tissue disease (MCTD). Although various platforms can be used to detect ANAs, an IFA with HEp-2 cells remains the gold standard1 because of its high sensitivity for several of the autoimmune rheumatic diseases.2 The high sensitivity stems from the large number of autoantigens (up to 150) in HEp-2 cells.
The diagnostic value of ANA testing varies with the specific clinical condition. For example, positive ANA results are required for diagnosis of drug-associated lupus and MCTD. Testing is also recommended when SLE or SSc are suspected. ANA testing may also be helpful in evaluating Sjögren syndrome and polymyositis/dermatomyositis.
1. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17-23.
2. American College of Rheumatology. Methodology of testing for antinuclear antibodies (position statement). https://www.rheumatology.org/(www.rheumatology.org). Published January 2009. Updated August 2015. Accessed December 5, 2017.
The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.